Gene therapy trial hopes to treat rare muscle disease

NCT ID NCT04174105

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 37 times

Summary

This early-stage study tests a gene therapy called AT845 for adults with late-onset Pompe disease, a condition that weakens muscles. The treatment aims to deliver a working copy of the GAA gene to muscle cells. Eleven participants who have been on standard enzyme replacement therapy for at least two years are enrolled. The study focuses on safety and whether the therapy can improve muscle function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POMPE DISEASE (LATE-ONSET) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Newcastle Upon Tyne Hospitals Foundation Trust Clinical Research Facility

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • Stanford University

    Palo Alto, California, 94304, United States

  • University of California Irvine, Department of Neurology

    Orange, California, 92868, United States

  • University of Utah, Division of Medical Genetics

    Salt Lake City, Utah, 84108, United States

Conditions

Explore the condition pages connected to this study.